Sugi Predict

Sugi Predict / Compounds / SCHEMBL1199986

SCHEMBL1199986

SCHEMBL1199986

O=C(O)c1cccc(C(=O)N2CCOCC2)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ TSHR P16473 3/20 0.64
▸ HPGD P15428 3/20 0.64
▸ KDM4E B2RXH2 1/20 0.62
▸ KMO O15229 1/20 0.62
▸ RECQL P46063 1/20 0.61
▸ USP2 O75604 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ L3MBTL3 Q96JM7 1/20 0.58
▸ PKM P14618 1/20 0.58
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ GAA P10253 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30577960 1.00 L3MBTL1 (0.64) L3MBTL1TSHRHPGDKDM4EKMO
SCHEMBL10720509 0.93 L3MBTL1 (0.71) L3MBTL1TSHRHPGDKDM4ERECQL
SCHEMBL4245858 0.92 HPGD (0.74) L3MBTL1TSHRHPGDKDM4EKMO
SCHEMBL3076585 0.89 TSHR (0.67) L3MBTL1TSHRHPGDKDM4ERECQL
SCHEMBL16719440 0.88 ACACB (0.58) L3MBTL1TSHRHPGDKDM4EKMO
SCHEMBL28294867 0.88 HPGD (0.71) L3MBTL1TSHRHPGDKDM4ERECQL
SCHEMBL3227656 0.85 MEN1 (0.63) L3MBTL1TSHRHPGDKDM4ERECQL
SCHEMBL7222464 0.85 HPGD (0.78) L3MBTL1TSHRHPGDKDM4ERECQL
SCHEMBL4248924 0.85 HPGD (0.73) TSHRHPGDKMOMAPK1ALDH1A1
SCHEMBL520601 0.85 KDM4E (0.90) L3MBTL1KDM4ELMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110088108-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 — — CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
CN-110099905-A SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-06 — — CN claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 — — CN claimed
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2026-01-29 — — US disclosed
CN-110088108-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 — — CN disclosed
CN-116655595-A 2, 6-piperidinedione derivatives, their preparation and use 中国人民解放军军事科学院军事医学研究院 2023-08-29 — — CN disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
US-20210308121-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2021-10-07 — — US disclosed
US-20110034462-A1 ORGANIC COMPOUNDS BAESCHLIN DANIEL KASPAR 2011-02-10 — — US disclosed
US-20090281069-A1 ORGANIC COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-11-12 — — US disclosed
US-20090239860-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 — — US disclosed
CN-101472892-A Organic compounds NOVARTIS AG (CH) 2009-07-01 — — CN disclosed
US-20090118261-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS ASTRAZENECA AB (SE) 2009-05-07 — — US disclosed
EP-2007723-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2008-12-31 — — EP disclosed
WO-2007115821-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-18 — — WO disclosed
EP-1710233-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE Kissei Pharmaceutical Co., Ltd. (JP) 2006-10-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210308121-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 L3MBTL1 982/4885TSHR 3498/4885HPGD 2677/4885
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 L3MBTL1 1082/4885TSHR 315/4885HPGD 3543/4885
US-20090239860-A1 NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE ADORA2A, ADORA2B, HTR1F L3MBTL1 682/4885TSHR 231/4885HPGD 3251/4885
US-20090118261-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS BRAF, RAF1, ARAF L3MBTL1 3550/4885TSHR 3412/4885HPGD 1530/4885
US-20090281069-A1 ORGANIC COMPOUNDS OTC, OAT, SLCO2B1 L3MBTL1 3329/4885TSHR 3454/4885HPGD 513/4885
US-20110034462-A1 ORGANIC COMPOUNDS OTC, OAT, SLCO2B1 L3MBTL1 3329/4885TSHR 3454/4885HPGD 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.